U.S. patent number RE40,300 [Application Number 10/927,663] was granted by the patent office on 2008-05-06 for carbon dioxide enhancement of inhalation therapy.
This patent grant is currently assigned to Research Development Foundation. Invention is credited to J. Vernon Knight, Nadezhda Koshkina, J. Clifford Waldrep.
United States Patent |
RE40,300 |
Waldrep , et al. |
May 6, 2008 |
**Please see images for:
( Certificate of Correction ) ** |
Carbon dioxide enhancement of inhalation therapy
Abstract
The present invention provides a method of increasing the
deposition of aerosolized drug in the respiratory tract of an
individual or animal, comprising the step of administering said
aerosolized drug in an air mixture containing up to about 10%
carbon dioxide gas.
Inventors: |
Waldrep; J. Clifford (The
Woodlands, TX), Knight; J. Vernon (Houston, TX),
Koshkina; Nadezhda (Houston, TX) |
Assignee: |
Research Development Foundation
(Carson City, NV)
|
Family
ID: |
22614028 |
Appl.
No.: |
10/927,663 |
Filed: |
August 26, 2004 |
Related U.S. Patent Documents
|
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
Issue Date |
|
|
60169038 |
Dec 4, 1999 |
|
|
|
Reissue of: |
09729468 |
Dec 4, 2000 |
06440393 |
Aug 27, 2002 |
|
|
Current U.S.
Class: |
424/45; 424/450;
424/458; 424/1.21; 424/1.13 |
Current CPC
Class: |
A61K
9/1271 (20130101); A61P 11/00 (20180101); A61K
9/1272 (20130101); A61K 9/0078 (20130101); A61P
43/00 (20180101); A61K 9/127 (20130101); A61K
9/124 (20130101); A61K 48/00 (20130101); Y10S
977/773 (20130101); Y10S 977/801 (20130101); Y10S
977/915 (20130101); Y10S 977/907 (20130101); Y10S
977/926 (20130101) |
Current International
Class: |
A61K
9/12 (20060101); A61K 9/127 (20060101) |
Field of
Search: |
;424/45,450,458,1.13,1.121 |
References Cited
[Referenced By]
U.S. Patent Documents
|
|
|
5049388 |
September 1991 |
Knight et al. |
5639441 |
June 1997 |
Sievers et al. |
5958378 |
September 1999 |
Waldrep et al. |
6090407 |
July 2000 |
Knight et al. |
6106859 |
August 2000 |
Desmore, Jr. et al. |
|
Other References
Davis and Staag, "Interrelationships of volume and time components
of individual breaths in resting man," J. Physiol.,245:481, 1975.
cited by other .
Densmore et al., "Gene transfer by guanidinium-cholesterol:
dioleoylphosphatidyl-ethanolamine liposome-DNA complexex in
aerosol," J. Gene Med.,1:251-264, 1999. cited by other .
Knight et al., "Anticancer effect of 9-nitrocamptothecin liposome
aerosol on human cancer xenografts in nude mice," Cancer Chemother.
Pharmacol., 44:177-186, 1999. cited by other .
Koshkina et al., "Distribution of camptothecin after delivery as a
liposome aerosol or following intramuscular injection in mice,"
Cancer Chemother. Pharmacol., 44:187-192, 1999. cited by other
.
Nielsen et al., "Ventilation, CO.sub.2 Production, and CO.sub.2
Exposure Effects in Conscious, Restrained CF-1 Mice," Pharmacol.
& Toxicol., 72:163-168, 1993. cited by other .
Persons et al., "Airway deposition of hygroscopic heterodispersed
aerosols: results of a computer model," J. Appl. Physiol.,
63:1195-1204, 1987. cited by other .
Persons et al., "Maximization of pulmonary hygroscopic aerosol
deposition," J. Appl. Physiol. 63:1205-1209, 1987. cited by other
.
Schlenker, "Ventilation and Metabolism of the Djungarian Hamster
(Phodopus Sungorus) and the Albino Mouse," Comp. Biochem. Physiol.,
82A(2):293-295, 1985. cited by other .
Stegen et al., "Negative affect, respiratory reactivity, and
somatic complaints in a CO.sub.2 enriched air inhalation paradigm,"
Biol. Psychol. 49:109-122, 1998. cited by other .
Vidgren et al., "A study of .sup.99mtechnetium-labelled
beclomethasone dipropionate dilauroylphosphatidylcholine liposome
aerosol in normal volunteers," Int. J. Pharm., 115:209, 1995. cited
by other .
Waldrep et al., "High dose cyclosporin A and budesonide-liposome
aerosols," Int. J. Pharm., 12:27, 1997. cited by other .
Co-Pending U.S. Appl. No. 09/540,916, filed Mar. 31, 2000. cited by
other .
Kim et al, International Journal of Pharmaceutics, 180(Dec. 1998)
pp. 75-81, Pharmacodynamics of insulin in polyrthylene
glycol-coated liposomes. cited by examiner.
|
Primary Examiner: Richter; Johann
Assistant Examiner: Haghighatian; Mina
Attorney, Agent or Firm: Fulbright & Jaworski,
L.L.P.
Parent Case Text
CROSS-REFERENCE TO RELATED APPLICATION
This patent application claims benefit of priority of provisional
application, U.S. Ser. No. 60/169,038, filed Dec. 4, 1999, now
abandoned.
Claims
What is claimed is:
1. A method of increasing the deposition of a drug into the
respiratory tract of an individual or animal during inhalation
therapy, comprising the steps of: mixing carbon dioxide gas with
air to form a carbon dioxide-air mixture, said carbon dioxide-air
mixture containing bout 7.5% to about 10% by volume carbon dioxide
gas; aerosolizing said drug in said carbon dioxide-air mixture
wherein prior to aerosolization said drug is a soluble drug
dissolved in a buffered solution or water or, in the alternative,
said drug is an insoluble or lipophilic drug carried by a liposome,
a sterically stabilized liposome, a slow release polymer or a
polycationic polymer; and administering said aerosolized drug
during inhalation therapy by continuously flowing said
carbon-dioxide-air mixture wherein carbon dioxide in said mixture
increases inhalation rate and inhaled volume of said aerosolized
drug thereby increasing deposition of said aerosolized drug into
the respiratory tract.
2. The method of claim 1, wherein said aerosol is administered for
a period of time from about 1 minute to about 30 minutes.
3. The method of claim 1, wherein said drug is aerosolized by a jet
nebulizer.
4. The method of claim 1, wherein said water soluble or buffer
soluble drug is selected from the group consisting of an
antibiotic, a mucolytic, a bronchodilator, a parasympathetic agent,
an enzyme and an anti-viral.
5. The method of claim 1, wherein said sterically stabilized
liposome is a poly(ethylene glycol) modified phospholipid.
6. The method of claim 5, wherein said poly(ethylene glycol)
modified phospholipid is dimyristoylphosphoethanolamine
poly(ethylene glycol) 2000.
7. The method of claim 1, wherein said lipophilic drug is selected
from the group consisting of amphotericin B, nystatin,
glucocorticoids, an immunosuppressive and an anti-cancer drug.
8. The method of claim 7, wherein said anti-cancer drug is selected
from the group consisting of camptothecin, 9-nitrocamptotecin, and
paclitaxel.
9. The method of claim 1, wherein said drug is selected from the
group consisting of therapeutic proteins, therapeutic peptides, DNA
genes, sense oligonucleotides, anti-sense oligonucleotides and
viral vectors.
10. The method of claim 9, wherein said DNA gene is chloramphenicol
acetyl transferase or p53.
11. The method of claim 9, wherein said DNA gene is delivered via a
polycationic polymer carrier.
12. The method of claim 11, wherein said polycationic polymer is
polyethylenimine.
13. The method of claim 12, wherein a ratio of polyethylenimine
nitrogen to DNA phosphate (nitrogen:phosphate) is about 10:1 to
about 20:1.
14. The method of claim 13, wherein said polyethylenimine
nitrogen:DNA phosphate ratio is 10:1.
15. The method of claim 1, wherein said liposome is formed from a
lipid comprising a phosphatidylcholine.
16. The method of claim 15, wherein said phosphatidylcholine is
dilauroylphosphatidylcholine.
.Iadd.17. A method of increasing the deposition of a drug into the
respiratory tract of a human, comprising the steps of: mixing
carbon dioxide gas with air to form a carbon dioxide-air mixture,
said carbon dioxide-air mixture containing up to 10% by volume
carbon dioxide gas; aerosolizing said drug in said carbon
dioxide-air mixture; and administering said aerosolized drug to a
human during inhalation therapy, wherein carbon dioxide in said
mixture increases inhalation rate and inhaled volume of said
aerosolized drug thereby increasing deposition of said aerosolized
drug into the respiratory tract..Iaddend.
.Iadd.18. The method of claim 17, wherein said aerosol is
administered for a period of time from about 1 minute to about 30
minutes..Iaddend.
.Iadd.19. The method of claim 17, wherein said drug is aerosolized
by a jet nebulizer..Iaddend.
.Iadd.20. The method of claim 17, wherein said carbon dioxide-air
mixture contains about 2.5% by volume carbon dioxide
gas..Iaddend.
.Iadd.21. The method of claim 17, wherein said carbon dioxide-air
mixture contains about 5% by volume carbon dioxide
gas..Iaddend.
.Iadd.22. The method of claim 17, wherein said carbon dioxide-air
mixture contains about 7.5% by volume carbon dioxide
gas..Iaddend.
.Iadd.23. A method of increasing the deposition of a drug into the
respiratory tract of an individual or animal during inhalation
therapy, comprising the steps of: mixing carbon dioxide gas with
air to form a carbon dioxide-air mixture, said carbon dioxide-air
mixture containing up to about 10% by volume carbon dioxide gas;
aerosolizing said drug in said carbon dioxide-air mixture wherein
prior to aerosolization said drug is a soluble drug dissolved in a
buffered solution or water; and administering said aerosolized drug
during inhalation therapy by continuously flowing said
carbon-dioxide-air mixture wherein carbon dioxide in said mixture
increases inhalation rate and inhaled volume of said aerosolized
drug thereby increasing deposition of said aerosolized drug into
the respiratory tract..Iaddend.
.Iadd.24. The method of claim 21, wherein said aerosol is
administered for a period of time from about 1 minute to about 30
minutes..Iaddend.
.Iadd.25. The method of claim 23, wherein said drug is aerosolized
by a jet nebulizer..Iaddend.
.Iadd.26. The method of claim 23, wherein said water soluble or
buffer soluble drug is selected from the group consisting of an
antibiotic, a mucolytic, a bronchodilator, a parasympathetic agent,
an enzyme and an anti-viral agent..Iaddend.
.Iadd.27. The method of claim 23, wherein said carbon dioxide-air
mixture contains about 2.5% by volume carbon dioxide
gas..Iaddend.
.Iadd.28. The method of claim 23, wherein said carbon dioxide-air
mixture contains about 5% by volume carbon dioxide
gas..Iaddend.
.Iadd.29. The method of claim 23, wherein said carbon dioxide-air
mixture contains about 7.5% by volume carbon dioxide
gas..Iaddend.
.Iadd.30. A method of increasing the deposition of a drug into the
respiratory tract of an individual or animal during inhalation
therapy, comprising the steps of: mixing carbon dioxide gas with
air to form a carbon dioxide-air mixture, said carbon dioxide-air
mixture containing up to about 10% by volume carbon dioxide gas;
aerosolizing said drug in said carbon dioxide-air mixture wherein
prior to aerosolization said drug is a lipophilic drug carried by a
liposome, wherein said lipophilic drug is selected from the group
consisting of amphotericin B, nystatin, glucocorticoids, an
immunosuppressive, and an anti-cancer drug; and administering said
aerosolized drug during inhalation therapy by continuously flowing
said carbon-dioxide-air mixture wherein carbon dioxide in said
mixture increases inhalation rate and inhaled volume of said
aerosolized drug thereby increasing deposition of said aerosolized
drug into the respiratory tract..Iaddend.
.Iadd.31. The method of claim 30, wherein said aerosol is
administered for a period of time from about 1 minute to about 30
minutes..Iaddend.
.Iadd.32. The method of claim 30, wherein said drug is aerosolized
by a jet nebulizer..Iaddend.
.Iadd.33. The method of claim 30, wherein said anti-cancer drug is
selected from the group consisting of captothecin,
9-nitrocamptothecin, and paclitaxel..Iaddend.
.Iadd.34. The method of claim 30, wherein said liposome is a
sterically stabilized liposome..Iaddend.
.Iadd.35. The method of claim 34, wherein said sterically
stabilized liposome is a poly(ethylene glycol) modified
phospholipid..Iaddend.
.Iadd.36. The method of claim 35, wherein said poly(ethylene
glycol) modified phospholipid is dimyristoylphosphoethanolamine
poly(ethylene glycol) 2000..Iaddend.
.Iadd.37. The method of claim 30, wherein said liposome is formed
from a lipid comprising a phosphatidylcholine..Iaddend.
.Iadd.38. The method of claim 37, wherein said phosphatidylcholine
is dilauroylphosphatidylcholine..Iaddend.
.Iadd.39. The method of claim 30, wherein said carbon dioxide-air
mixture contains about 2.5% by volume carbon dioxide gas..Iaddend.
.Iadd.40., The method of claim 30, wherein said carbon dioxide-air
mixture contains about 5% by volume carbon dioxide
gas..Iaddend.
.Iadd.41. The method of claim 30, wherein said carbon dioxide-air
mixture contains about 7.5% by volume carbon dioxide
gas..Iaddend.
.Iadd.42. A method of increasing the deposition of a drug into the
respiratory tract of an individual or animal during inhalation
therapy, comprising the steps of: mixing carbon dioxide gas with
air to form a carbon dioxide-air mixture, said carbon dioxide-air
mixture containing up to about 10% by volume carbon dioxide gas;
aerosolizing said drug in said carbon dioxide-air mixture wherein
said drug is carried by a polymer or a slow release polymer or
polycationic polymer; and administering said aerosolized drug
during inhalation therapy by continuously flowing said
carbon-dioxide-air mixture wherein carbon dioxide in said mixture
increases inhalation rate and inhaled volume of said aerosolized
drug thereby increasing deposition of said aerosolized drug into
the respiratory tract..Iaddend.
.Iadd.43. The method of claim 42, wherein said aerosol is
administered for a period of time from about 1 minute to about 30
minutes..Iaddend.
.Iadd.44. The method of claim 42, wherein said drug is aerosolized
by a jet nebulizer..Iaddend.
.Iadd.45. The method of claim 42, wherein said drug is selected
from the group consisting of therapeutic proteins, therapeutic
peptides, DNA genes, sense oligonucleotides, anti-sense
oligonucleotides, and viral vectors..Iaddend.
.Iadd.46. The method of claim 45, wherein said DNA gene is
chloramphenicol acetyl transferase or p53..Iaddend.
.Iadd.47. The method of claim 42, wherein said polycationic polymer
is polyethylenimine..Iaddend.
.Iadd.48. The method of claim 47, wherein as ratio of
polyethylenimine nitrogen to DNA phosphate (nitrogen:phosphate) is
about 10:1 to about 20:1..Iaddend.
.Iadd.49. The method of claim 48, wherein said polyethylenimine
nitrogen:DNA phosphate ratio is 10:1..Iaddend.
.Iadd.50. The method of claim 42, wherein said carbon dioxide-air
mixture contains about 2.5% by volume carbon dioxide
gas..Iaddend.
.Iadd.51. The method of claim 42, wherein said carbon dioxide-air
mixture contains about 5% by volume carbon dioxide
gas..Iaddend.
.Iadd.52. The method of claim 42, wherein said carbon dioxide-air
mixture contains about 7.5% by volume carbon dioxide gas..Iaddend.
Description
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates generally to the fields of
pharmacology and drug delivery. More specifically, the present
invention relates to a method of using carbon dioxide gas to
increase pulmonary deposition of an aerosolized drug during
inhalation therapy.
2. Description of the Related Art
Small particle liposome aerosol treatment consists of lipid-soluble
or water-soluble anti-cancer drugs incorporated into liposomes,
which are administered from aqueous dispersions in a jet nebulizer
(see U.S. Pat. No. 5,049,388). Aerosols of 1-3 .mu.m mass median
aerodynamic diameter, generated upon nebulization, enable targeted
delivery onto surfaces of the respiratory tract. The deposited
liposomes subsequently release drug locally within the lung or into
the blood circulation with delivery to extra-pulmonary tissue.
If the drug is lipid soluble, it will associate with the lipid
molecules in a manner specific to the lipid employed, the
anti-cancer drug employed and possibly it may be modified further
by various soluble constituents which may be included in the
suspending aqueous medium. Such soluble constituents may include
buffering salts and possibly inositol to enhance the synthesis and
secretion of surfactant phospholipid in lung tissue and to minimize
respiratory distress already present or that which might result
from the aerosol treatment (7).
If the drug is water soluble, it may be incorporated by appropriate
procedures in aqueous vesicles that exit in concentric spaces
between lipid bilayers (lamellae) of the multilamellar liposome.
Unilamellar liposomes may be prepared; however, their capacity to
entrap either lipid-soluble or water-soluble drugs is diminished
since entrapment is restricted to one central vesicle. Aerosol
water droplets may contain one or more drug-liposomes. Moreover, it
is also possible to incorporate more than one drug in a aerosol
liposome treatment, either by mixing different drug-containing
liposomes, or by using liposomes wherein the drugs have been
combined and incorporated together into liposomes.
Nebulization shears liposomes to sizes readily discharged from the
nozzle of the nebulizer. Liposomes up to several microns in
diameter are typically sheared to diameters of less than 500 nm,
and may be considerably smaller than that depending on the
operating characteristics of the nebulizer and other variables.
Shearing of water-soluble drugs contained in liposomes will release
appreciable amounts of the water soluble compound, perhaps 50
percent. This is not a contraindication to their use, but it means
that two forms of the drug preparation is administered, and the
effect includes the therapeutic effect that would be produced by
both forms if either form has been given alone. Many other details
of liposome aerosol treatment are described in U.S. Pat. No.
5,049,388.
In general, the underlying objective of inhalation therapy is the
topical delivery of aerosolized particles of pharmaceutical drugs
into the central airways and to peripheral regions of the
respiratory tract. However, the deposition fraction of the inhaled
particles even for the optimal size range of 1-2 .mu.m mass median
aerodynamic diameter is only approximately 20%. Pulmonary
deposition of inhaled aerosols is influenced significantly by
particle size, hygroscopic properties and airway geometry (1,2).
The breathing pattern is also an important variable that determines
the deposition pattern of inhaled particles (1,2).
Specifically, breath holding markedly increases pulmonary
deposition due to increased residence time of particles within the
lung. This allows a longer period for gravity sedimentation to
occur especially in the small peripheral airways and to ensure that
the aqueous particles can equilibrate fully in the near 100%
humidity and reach their maximum size, which further enhances their
deposition (1,2). Computer simulations demonstrate that a
thirty-second breath holding maneuver in humans can increase the
deposition fraction 3.2 times. The physiological principle of this
effect is due to increased particle intake upon deep inspiration in
which the inhaled volume may be as much as 8-fold higher than the
amount inhaled with basal tidal breathing. This larger volume of
tidal breathing leads to penetration of particles to the furthest
recesses of the lung where airway diameters are smallest, and thus
deposition due to gravity and maximum particle size occurs with
greatest efficiency.
By extension of this physiological property, direct utilization of
factors which could increase the volume of inspired air (containing
aerosol particles) would subsequently markedly increase the
deposited fraction in the central airway and to an even greater
extent in the peripheral lung. Carbon dioxide (CO.sub.2) is the
most important natural regulator of respiration. Carbon dioxide
diffuses freely from the tissues into the blood according to the
existing pressure gradient. Increased levels of carbon dioxide in
the blood readily diffuse into the cerebrospinal fluid where there
is conversion into HCO.sub.3.sup.- and H.sup.+. Central
chemoreceptors on the ventral surface of the medulla respond to
increased H.sup.+ in the CSF and cause a compensatory increase in
ventilation (rate and tidal volume).
Investigators have utilized carbon dioxide inhalation to manipulate
ventilation in experimental animals and humans. Inhalation of 5%
carbon dioxide causes as much as 192% increase in tidal volume (3).
This increase is rapid and reaches a sustained plateau throughout
the duration of exposure (4). Once the carbon dioxide exposure
ceases, the changes in ventilation reverse within minutes to basal
level (4). Similarly, inhalation of 5% carbon dioxide by humans
results in a 3-fold increase in the minute volume (5). Inhalation
of 5% or 7.5% of carbon dioxide by normal humans for two minutes
resulted in increases in frequency of breathing by 6.7% and 19%,
respectively, and increases in tidal volumes by 31% and 52%,
respectively, so that minute volumes were increased by 34% and 75%,
respectively (6). Longer exposures to these concentrations would
have produced even greater responses (5).
Camptothecin analogues and taxanes are chemical agents currently
being developed as chemotherapeutic agents (21, 26). The anticancer
drugs, paclitaxel (PTX) and different camptothecin (CPT)
derivatives are clinically active in the treatment of a variety of
human tumors, including lung cancer. These drugs show beneficial
results in clinical trails when used as single agents or in
combination with other drugs (21). These drugs are given
systemically by oral or intravenous routes of administration; the
most effective route for paclitaxel is continuous intravenous
infusion (22,24) whereas lipophilic congeners of camptothecin
administrated orally prove most effective. The development of toxic
side effects is often a major limitation in such therapeutic
regimens. Several subcutaneous human cancer xenografts in nude mice
(23) and in experimental murine pulmonary metastasis (6) have been
successfully treated using liposomal formulations of camptothecin
and 9-nitrocamptothecin (9NC) administered by the aerosol route as
an alternative method of therapy. Pharmacokinetic studies in mice
with camptothecin showed that inhalation of liposomal camptothecin
produced substantial drug levels in the lungs and other organs,
which cleared rapidly after cessation of aerosol delivery (17). In
spite of these levels, aerosol delivery systems are generally only
15-20% efficient in drug deposition (29, 30); thus increasing
pulmonary deposition would be advantageous.
Using these systemic routes of drug delivery, a certain amount of
drug egresses from the blood stream and localizes in the
respiratory tissue, but lungs are not the main organs for drug
deposition. The utilization of conventional liposomes are carriers
for these drugs does not improve the pulmonary deposition of drugs
administered by commonly used systemic routes ( 11,27).
Nebulization is a very effective route for target drug delivery to
the respiratory tract (17); e.g., camptothecin. Dogs with
spontaneously arising primary and metastatic lung tumors have been
successfully treated when new formulations of doxorubicin and PTX
are delivered via aerosolization (16). However in these instances,
aerosols were generated using normal air.
Gene delivery to different tissues has been accomplished using both
viral and nonviral vectors. Although the use of nonviral vectors
avoids the immunogenic response associated with viral vectors,
nonviral vectors, such as cationic lipids and polycationic
polymers, have not been associated generally with the high levels
of gene expression characteristic of viral vectors. However,
polyethyleneimine (PEI), a cationic polymer, is effective both in
tissue culture and in vivo (36). The protonable nitrogen on every
third nitrogen provides polyethyleneimine with a huge buffering
capacity. Polyethyleneimine can effectively traffic DNA to the
nucleus (37) and protect DNA against DNAse degradation (36). Both
linear and branched forms of polyethyleneimine have been shown to
produce high levels of transgene expression in various tissues such
as lung, brain, and kidney (39-41). Polyethyleneimine has also been
used to efficiently deliver DNA to tumors in vivo (42).
Aerosol delivery is a noninvasive way to deliver genes of interest
to the lungs and could potentially be used to treat diseases such
as lung cancer and cystic fibrosis. However, the levels of
transgene expression have not been very high due, in some cases, to
loss of DNA viability during nebulization (43). PEI can protect the
DNA during nebulization (44) and can result in higher levels of
transfection in the lung than most of the other cationic lipids
tested (44,45). PEI-mediated transfection is also resistant to
inhibition by lung surfactants (46).
Increased efficiency of drug deposition to the respiratory tract by
the inhalation route is achieved by several ways: 1) changing the
concentration of drug in the formulation used for aerosolization
(31); 2) using more efficient types of nebulizers (32); 3)
increasing the duration of treatment; or 4) changing the breathing
patterns (4). As previously stated, carbon dioxide is a natural
modulator of respiration. The inhalation of air containing low
concentrations of CO.sub.2 (from about 3-7%) caused similar changes
in breathing patterns and was tolerated well (13, 6). No difference
in breathing patterns was observed between inhalation of 5%
CO.sub.2-in-air and moderate physical exercise in man (32). Similar
effects of 5% CO.sub.2-in-air may be obtained in man using aerosol
treatment. Thus utilization of CO.sub.2-enriched air for
nebulization as a modulator of inhalation therapy can result in
more effective pulmonary delivery of chemotherapeutic agents.
The prior art is deficient in the lack of a means of enhancing the
pulmonary deposition of an aerosolized drug during inhalation
therapy. The present invention fulfills this longstanding need and
desire in the art.
SUMMARY OF THE INVENTION
The present invention provides a method of increasing the
deposition of aerosolized drug in the respiratory tract of an
individual or animal, comprising the step of administering said
aerosolized drug in an air mixture containing up to about 10%
carbon dioxide gas. 2.5%, 5%, and 7.5% carbon dioxide
concentrations have been used herein. The aerosol may be
administered for 1 to 30 minutes or even longer. The administered
drug may be a soluble drug, an insoluble drug or a therapeutic
composition, e.g., oligonucleotide, gene, peptide, or protein, that
may be dissolved in solution and directly aerosolized with a jet
nebulizer or incorporated into a carrier such as liposomes, slow
release polymers or polycationic polymers prior to
aerosolization.
Other and further aspects, features, and advantages of the present
invention will be apparent from the following description of the
presently preferred embodiments of the invention given for the
purpose of disclosure.
BRIEF DESCRIPTION OF THE DRAWINGS
So that the matter in which the above-recited features, advantages
and objects of the invention, as well as others which will become
clear, are attained and can be understood in detail, more
particular descriptions of the invention briefly summarized above
may be had by reference to certain embodiments thereof which are
illustrated in the appended drawings. These drawings form a part of
the specification. It is to be noted, however, that the appended
drawings illustrate preferred embodiments of the invention and
therefore are not to be considered limiting in their scope.
FIG. 1 shows the tissue distribution of camptothecin after a 30 min
exposure to liposome aerosol generated with normal air (solid) or
with 5% CO.sub.2-enriched air (hatched). At the end of treatment
(30 min) organs from three mice per group are resected and the drug
content determined by HPLC. Mean values with SD are calculated. P
values for 5% CO.sub.2-air compared to normal air are 0.02, 0.13,
0.04, 0.04, 0.03, and 0/01 for lungs, liver, spleen, kidney, blood
and brain, respectively (Student's t-test, two-tailed).
FIG. 2 shows the pulmonary concentration-time curve for
CPT-liposomes administered for 30 min. by aerosol generated with
normal air (O) or with 5% CO.sub.2-enriched air (.circle-solid.).
For each time point lungs from three mice are resected and the drug
content determined by HPLC. Mean values with SD are calculated.
FIG. 3 shows the pulmonary concentration-time curve for
PTX-liposomes administered for 30 min. by aerosol generated with
normal air (O) or with 5% CO.sub.2-enriched air (.circle-solid.).
For each time point lungs from three mice are combined and the drug
content determined by HPLC. Each experiment is repeated three times
and mean values with SD are calculated.
FIG. 4 shows the comparison of tissue paclitaxel levels in the
lungs of mice exposed to aerosols containing different liposomal
formulations. Equivalent levels of exposure to paclitaxel are
achieved in a 5% CO.sub.2-in-air aerosol of sterically stabilized
paclitaxel-liposomes prepared from dimyristylphosphoethanolamine
poly (ethylene glycol) 2000 as when DLPC is utilized.
FIG. 5 shows the comparison between CAT expression in lung by
PEI-DNA aerosol generated using air or air containing 5% CO.sub.2.
One milligram of CAT plasmid was complexed with PEI at an N:P ratio
of 10:1 and the resulting complex aerosolized to mice for 30 min.
The lungs are harvested after 24 h and the CAT assay is performed
as described. Values are means.+-.SD (n=6 mice per group,
P=0.001).
FIG. 6 shows the effect of percent CO2 on the efficiency of PEI-DNA
transfer to the lung by aerosol. Different percentages of
CO2-in-air are used with a fixed amount of CAT plasmid. The
complexes were aerosolized using 0%, 2.5%, 5%, 10% carbon dioxide
and control. Mice are sacrificed, the lungs harvested, and the CAT
assay was performed. Values are expressed as means.+-.SD.
FIG. 7 shows that the gene expression in lung by PEI-DNA aerosol
was dose dependent. Increasing doses of CAT plasmid were
aerosolized using 5% CO.sub.2-in-air at a fixed N:P ratio of 10:1.
There is an increase in both the total amount of DNA delivered and
the concentration of PEI-DNA delivered. Mice were sacrificed after
24 h, the lungs are harvested, and the Cat protein is assayed.
Values are means.+-.SD (n=5 mice per group).
FIG. 8 shows the effect of N:P ratios on the efficiency of PEI-DNA
transfer to the lung by aerosol. Different PEI-DNA(N:P) ratios are
used with a fixed amount CAT plasmid (2 mg). The complex is
aerosolized using 5% CO.sub.2-in-air. Mice are sacrificed after 24
h, the lungs are harvested, and the CAT assay is performed. Values
are means.+-.SD (n=5 mice per group).
FIG. 9 shows the effect of N:P ratios on luciferase gene expression
in the lung. A fixed amount of luciferase plasmid (2 mg) is
delivered at different N:P ratios. The complexes are aerosolized
using 5% CO.sub.2-in-air. Mice are sacrificed 24 h after aerosol
delivery, lungs are harvested, and luciferase activity is
determined. Values are means.+-.SD (n=5 mice per group).
FIG. 10 shows the time course of transgene expression after single
PEI-DNA aerosol exposure.
In FIG. 10A mice are delivered an aerosol containing 2 mg of CAT
plasmid at a N:P ratio of 15:1 using 5% CO.sub.2-in-air. Mice are
sacrificed at different time points and the lungs are harvested and
immediately frozen. The CAT assay is performed after the last time
point. Values are means.+-.SD (n=5 mice per time point).
FIG. 10B shows the persistence of CAT expression using two
different N:P ratios. Both groups of mice (n=5 mice each per time
point per group) are delivered 2 mg of CAT plasmid at a 15:1 or
10:1 NPP ratio using 5% CO.sub.2-in-air. The time points for the
10:1 ratio are 1, 2, 3, and 6 days post aerosol exposure and for
the 15:1 ratio are 1, 3, 7, and 10 days post aerosol exposure.
FIG. 11 shows tissue distribution of transgene after single PEI-DNA
aerosol exposure. The same groups of mice are used as in FIG. 9
(from the 10:1 group). Different tissues are harvested and
immediately frozen. The CAT protein is assayed after the last time
point. Values are means.+-.SD (n=5 mice per time point). Levels of
CAT in non-lung tissues in the aerosol-exposed group are not
different from the control tissues (P>0.1).
FIG. 12 shows the histologcial analysis of PEI-DNA aerosol-treated
lungs. Two milligrams of CAT plasmid is complexed with PEI at a N:P
ratio of 15:1 and the complex was aerosolized to five mice for 30
min using 5% CO.sub.2-in-air. Mice are sacrificed 24 h later and
lungs are harvested and fixed in formalin. Thin sections are
stained with hemtoxylin and eosin (H&E). FIG. 12A: bronchiole
(control); FIG. 12B: bronchiole (treated). Magnification
100.times..
FIG. 13 shows the inhibition of B16-F10 lung metastasis by PEI-p53
aerosol delivery.
FIG. 13A: Tumor index was calculated by the formula: Tumor
index=lung weights.times.average grade for the group. Values are
means.+-.SD (n=10 mice per group).
FIG. 13B: Representative lungs from control, PEI-Lucand PEI-p53
treated mice are presented (n=10 mice per group). Lungs from
PEI-treated group (not shown) are similar in shape, size, and
number of tumor foci to those shown for control and PEI-Luc-treated
groups. Data are representative of two separate experiments.
FIG. 13C: Lung weights of mice from different groups. Values are
means.+-.SD (n=10 mice per group).
DETAILED DESCRIPTION OF THE INVENTION
The present invention provides a method of increasing the
deposition of aerosolized drug in the respiratory tract of an
individual or animal, comprising the step of administering said
aerosolized drug in an air mixture containing up to about 10%
carbon dioxide gas. Preferred concentrations include 2.5%, 5% and
7.5% carbon dioxide gas. The aerosol may be administered for 1 to
30 minutes or even longer.
The instant invention is directed to the aerosol delivery of a
water soluble drug. Such a drug may be directly prepared as a water
solution or a buffered solution and directly aerosolized.
Representative water soluble drugs include antibiotics like
tobramycin and pentamidine; muclolytics like acetyl cytsteine;
bronchodilators like albuterol; parasympathetic agents like
ipratropium bromide; enzymes like DNase; and anti-virals like
ribavirin.
Alternatively, the instant invention may be used to deliver an
insoluble drug that is associated with a carrier prior to aerosol
delivery. Possible carriers include liposomes, slow release
polymers and polycationic polymers. Liposomes are an especially
useful carrier for lipophilic drugs such as amphotericin B;
nystatin; glucocorticoids; immunosuppressives like CsA, FK506,
rapamycin or mycophenolate; and anti-cancer drugs like
camptothecin, camptothecin derivatives, and paclitaxel. The
liposomes may be formed from such lipids as the phospholipid
dilauroylphosphatidylcholine (DLPC) or they may be sterically
stabilized liposomes formulated with modified phospholipids such as
dimyristylphosphoethanolamine poly(ethylene glycol) 2000. Slow
release polymers, such as poly(lactic acid-co-glycolic acid)
(PLGA), or polycationic polymers, such as polyethyleneimine (PEI),
may be utilized.
The instant invention may also be applied to the delivery of
therapeutic proteins, therapeutic peptides, DNA genes, sense
oligonucleotides, anti-sense oligonucleotides, and viral vectors.
Representative examples of DNA genes are the chloramphenical acetyl
tranferase gene (CAT) or the p53 gene. Preferably, these genes are
delivered via a polycationic polymer carrier such as
polyethylenimine. Cationic liposomes also may be utilized as
carriers. The polyethylenimine may have a nitrogen:phosphate ratio
from about 10:1 to about 20:1. In a preferred embodiment, the PEI
nitrogen:phosphate ratio is about 10:1.
The following definitions are provided. Terms not specifically
defined area meant to be interpreted as is customary in the
art.
As used herein, the term "aerosols" refers to dispersions in air of
solid or liquid particles, of fine enough particle size and
consequent low setting velocities to have relative airborne
stability (8).
As used herein, the term "liposome aerosols" refers to aqueous
droplets within which are dispersed one or more particles of
liposomes or liposomes containing one or more medications intended
for delivery to the respiratory tract of humans or animals (9).
As used herein, the size of the aerosol droplets defined for this
application are those described in U.S. Pat. No. 5,049, 338, namely
mass median aerodynamic diameter (MMAD) of 1-3 .mu.m with a
geometric standard deviation of about 1.8-2.2. However, with low
concentrations of 9-NC and possibly other camptothecin derivatives,
the mass median aerodynamic diameter may be less than 1 .mu.m, such
as 0.8 .mu.m. Based on the studies disclosed by the present
invention, the liposomes may constitute substantially all of the
volume of the droplet when it has equilibrated to ambient relative
humidity.
As used herein, the "Weibel Lung Model" refers to a classification
of the structure of the human lungs that recognizes 23 consecutive
branchings of the airways of humans. The trachea is labeled 0,
bronchi and bronchioles extend through branches 16. These portions
of the airways contain ciliated epithelium and mucus glands.
Together they constitute the mucociliary blanket. Branchings 17-23
compose the alveolar portion of the lung and do not have a
mucociliary blanket. Thus, particles deposited here are not carried
up the airway to be swallowed.
It is postulated herein that under controlled experimental
conditions of hypercapnia, deposition of inhaled drug particles
would greatly increase over levels observed during basal tidal
breathing conditions. The use of carbon dioxide gas/air mixtures to
drive continuous flow jet nebulizers could greatly increase the
efficiency of the drug dose delivered to the peripheral lung
(Weibel's generations 17-23). By analogy, this system could be
effectively utilized to increase the biological efficiency of
inhaled drugs. This concept could be theoretically employed with
any drug, gene, oligonucleotide, or protein/peptide formulation
(soluble, liposomal, crystalline, or polymer-based carrier such as
polyethylenimine) and any gas or air driven jet nebulizer
The current invention is primarily directed toward the use of
carbon dioxide gas to increase the depth and frequency of breathing
during inhalation therapy with as aerosolized drug to result in
increased minute volumes. The increased tidal lung volume results
in enhanced pulmonary deposition of the inhaled drug particles,
particularly in the lung periphery which may not be fully
ventilated at low levels of breathing. The increased minute volume
resulting from increased frequency and greater depth of breathing
both contribute to the increased minute volume.
Administering an aerosolized drug in an air mixture containing up
to about 10% carbon dioxide gas results in increased deposition of
the drug in the respiratory system, measurably improving efficiency
and therapeutic efficacy of the aerosol drug delivery. Preferred
concentrations include 2.5%, 5% and 7.5% carbon dioxide gas. The
aerosol may be administered for 1 to 30 minutes or even longer. The
enhancing effect of the carbon dioxide is evident within 30
seconds. The respiratory effects of carbon dioxide are transient
and can be employed repeatedly.
The following examples are given for the purpose of illustrating
various embodiments of the invention and are not meant to limit the
present invention in any fashion.
EXAMPLE 1
Materials
PTX was obtained from Xechem (New Brunswick, N.J.). CPT was
obtained from Sigma (St. Louis, Mo.) and 9NC from ChemWerth
(Woodbridge, Conn.). Dilauroylphosphatidylcholine (DLPC) was
purchased from Avanti Polar Lipids (Alabaster, Ala.). DMSO was
purchases from Sigma (St. Louis, Mo.) and HPLC grade other organic
solvents were obtained from Fisher Scientific. Sterile water for
irrigation came from Baxter Healthcare Corporation (Deerfield,
Ill.).
ICR mice (7-8 weeks old) were obtained from Harlan-Sprague Dawley
(Indianapolis, Ind.) and housed in standard cages with food and
water provided ad libitum. Female C57BL/6 mice (8-9 weeks old) and
female Balb/C mice (5-7 weeks old) were obtained from
Harlan-Sprague Dawley (Houston, Tex.). All animal care was in
accordance with Baylor College of Medicine Institutional Animal
Care and Use Committee.
The bacterial chloramphenicol acetyl transferase gene (CAT, p4119,
Ref. 15) is primarily used as the reporter gene for measuring
transgene expression. The CAT gene is under the control of human
cytomegalovirus (CMV) early promoter/enhancer element. The
luciferase plasmid (pGL3, Promega, Madison, Wis.) modified by
insertion of the CMV promoter/enhancer element and the human growth
hormone polyadenylation sequence was a gift from Dr. Michael Barry
(Center for Cell and Gene Therapy, Baylor). All plasmids are
purified on Qiagen columns (Qiagen, Valencia, Calif.) and are
endotoxin free. The plasmids are quantitated by UV absorbance at
260 nm. Agarose gel analysis is revealed th plasmids to be a
mixture of primarily supercoiled plasmid with a small amount of
nicked plasmid.
The plasmid containing the p53 gene was obtained from Dr. Y. K.
Fung (Children's Hospital, Los Angeles, Calif.). The p53 gene is
under the control of human cytomegalovirus (CMV) promoter/enhancer
element. The plasmid used as a control contains the firefly
luciferase (Luc) gene and was obtained from Dr. Michael Barry
(Baylor College of medicine). The plasmids were purified
commercially by Bayou Biolabs (Harahan, La.), were endotoxin free
and were quantitated using UV absorbance. Agarose gel analysis
revealed the plasmids to be primarily in the supercoiled form with
a small amount of nicked plasmid.
B16-F10 melanoma cell line was obtained from Division of Cancer
treatment and Diagnosis Center (DCTDC, NCE, Frederick, Md.) and
cultivated in DMEM supplemented with 10% fetal calf serum. The cell
line has been shown to form tumors in the lung (15). Twenty-five
thousand B16-F10 cells in 200 .mu.l of media are injected per mice
via the tail vein of C57BL/6 mice. Lung metastases are visually
detected within 2 weeks after inoculation of cells. The cells were
used at passages 3-12.
EXAMPLE 2
Statistics
After performing one-way analysis of variance (ANOVA) to compare
the means, a two-tailed unpaired Student's t test was done. A
difference was considered significant if P.ltoreq.0.05.
EXAMPLE 3
Preparation of Liposomes
Stock solutions of DLPC, PTX and camptothecin are prepared in
t-butanol at 100, 10 and 1 mg/ml, respectively, using previously
described methods (17). Aliquots of paclitaxel and DLPC are mixed
at a weight ratio of 1:10. The camptothecin to DLPC weight ratio is
1:50. The drug-phospholipid mixture is then frozen in liquid
nitrogen and lyphilized overnight to a dry powder. The formulations
are stored sealed at -20.degree. C. Before use the mixture is
reconstituted with sterile water for irrigation and vortexes until
a homogeneous multi-lamellar liposomal suspension is obtained. The
initial concentrations of camptothecin and paclitaxel in suspension
prior to nebulization are 0.5 mg/ml and 10 mg/ml, respectively. The
size of liposomes before and after nebulization is determined using
Nicomp Submicron Particle Sizer Model 370 9NICOMP, Santa Barbara,
Calif.).
EXAMPLE 4
Aerosol Particle Size Characteristics
The characteristics of aerosol particles containing liposomal
encapsulated drugs are estimated using an Andersen/AFCM nonviable
ambient particle sizing sampler (Andersen Instruments, Atlanta,
Ga.) as described (31). The concentration of drug in aerosols
produced by air or gas mixtures flowing at 10 L/min through
AERO-MIST nebulizer is also measured by collecting samples for 3
min starting one minute after aerosolization initiation. The mass
median aerodynamic diameter (MMAD) and geometric standard deviation
(GSD) are calculated as described (30, 31) using KaleidaGraph 2.0
software (synergy Software, Reading, Pa.).
EXAMPLE 5
Aerosol Delivery of Paclitaxel and Camptothecin
The treatment of mice with aerosol is performed as previously
described (16-18). Briefly, an AERO-MIST jet nebulizer (CIS-USA,
Bedford, Mass.) is used to generate aerosol particles at the air
flow rate of 10 L/min. Mice are placed in sealed plastic cage
(23.times.18.times.13 cm) and exposed to aerosol for 30 min. The
aerosol is generated with normal or 5% CO.sub.2-enriched air
obtained by mixing normal air and CO.sub.2 with a blender (Bird 3m,
Palm Springs, Calif.) and the CO.sub.2 concentrations are
calibrated with a Fluid Fyrite (Bacharach Inc., Pittsburgh, Pa.).
At each time point 3 mice are removed from the cage and sacrificed
by exposure to Isoflurane, USP (Abbott Laboratories, Chicago, Ill.)
and exsanguination. Organs are resected, weighed and kept frozen at
-70.degree. C. until extraction.
EXAMPLE 6
Extraction of Drug From Tissues
Before extraction, samples are thawed and immediately cut in small
pieces with scissors. To extract paclitaxel from tissues, 3 ml of
ethylacetate is added to each sample and homogenized in a
mini-beadbeater (Wig-L-Bud, Model 3110B, Crescent Dental MFR. Co.,
Lyons, Ill.) for 2 min. Homogenates are transferred to 10 ml
conical glass centrifuge tubes and centrifuged at 1,000.times.g for
10 min. The supernatant fraction is separated and organic solvent
is evaporated with air. The residue is reconstituted in 0.2 ml of
methanol:acetonitrile (2:1, v/v), sonicated in a water-bath
sonicator and centrifuged at 1,000.times.g for 10 min. Supernatant
fractions are warmed at 37.degree. C. for 30 min and analyzed by
HPLC.
The extraction procedure for camptothecin and 9NC is as previously
described (17). Briefly, after thawing tissue, 20 .mu.g of 9NC in
20 .mu.l is added in organs as an internal standard to determine
the extraction efficiency. The samples are cut in small pieces and
1 ml of 0.1% aqueous acetic acid solution, pH 3.2 is added to each
sample. After the homogenization in a mini-beadbeater, the
homogenates are centrifuged at 1,000.times.g for 5 min. The
supernatant fractions are re-extracted with 8 ml of methylene
chloride. The organic fraction is separated and dried under air at
room temperature. The dried samples are reconstituted in 0.2 ml of
acetronitrile.
EXAMPLE 7
HPLC Analysis
Paclitaxel is quantified by reverse-phase HPLC monitoring on a
Waters 486 UV absorbance detector at 227 nm (Waters, Milford,
Mass.). All measurements are made at room temperature on Waters
Nova-Pak C18 column (3.9.times.150 cm). The mobile phase is
composed of 49% acetronitrile and 51% water. The flow rate ia 1.5
ml/min. A 25 .mu.l aliquot of each sample is injected and data is
analyzed with Waters millennium Software. For PIX extraction
efficiency determination, identical procedures are performed when a
known amount of paclitaxel is added to each tissue and compared to
the extracted amount of paclitaxel. The extraction efficiency (%)
is calculated as ((amount of paclitaxel after extraction)/(amount
of added paclitaxel)).times.100. For all tested tissues the average
extraction efficiency is 89.+-.4% (data not shown) and this index
is used to calculate the final concentrations of drug in the
tissues.
HPLC analysis of camptothecin is performed using a Waters NovaPak
C18 column (3.9.times.150 cm) (17). Chromatograms for camptothecin
are monitored on Waters 470 scanning fluorescent detector
(.lamda.ex=360 nm, .lamda.em=455 nm) while 9NC is detected using
Waters 440 UV absorbance detector monitoring at 254 nm. The mobile
phase is composed of 30% acetonitrile and 70% of 0.1% acetic acid
solution in water, pH 3.5 at a flow rate 1.2 ml/min (16,17).
EXAMPLE 8
Aerosol Characteristics of Liposome Formulations
The properties of CPT-DLPC and PTX-DLPC liposomes and their aerosol
characteristics are summarized in Table 1. The utilization of
5%CO.sub.2-air did not change the concentration of either drug in
the aerosol or their MMAD and GSD (P>0.1; Student's t-test,
two-tailed). The nebulization procedure reduces the size of
liposome particles in solution from micron- to nano-particles for
both drug formulations. The size of liposomes of CPT-DLPC decreased
from 2.54.+-.0.91 .mu.m before nebulization to 0.49.+-.0.07 .mu.m
after nebulization using the 5% CO.sub.2-air mixture. For the
PTX-DLPC formulation these values are 13.14.+-.12.15 .mu.m and
0.23.+-.0.17 .mu.m, respectively. The aerosol particle size before
or after nebulization is not different for either PTX-DLPC or
CPT-DLPC administered by aerosol using normal or 5% CO.sub.2-air
(P>0.5; Student's t-test, two-tailed).
TABLE-US-00001 TABLE 1 Aerosol and liposome characteristics for
PTX-DLPC and CPT-DLPC formulations using 5% CO2-air versus normal
air Drug Liposome particle size, Concentration Aerosol droplets
.mu.m Drug Air in Aerosol, MMAD Before After Formulation
Composition .mu.g/L .mu.m GSD Nebulization Nebulization CPT-DLPC,
Normal 9.0 .+-. 1.3 1.6 .+-. 0.3 2.1 .+-. 0.1 3.72 .+-. 1.10 0.34
.+-. 0.11 0.5 mg CPT/ml 5% CO2 9.2 .+-. 1.9 1.7 .+-. 0.5 2.3 .+-.
0.2 2.54 .+-. 0.91 0.49 .+-. 0.07 PTX-DLPC, Normal 153.0 .+-. 27
2.0 .+-. 0.2 1.8 .+-. 0.03 12.49 .+-. 8.06 0.13 .+-. 0.18 10 mg
PTX/ml 5% CO2 175.0 .+-. 9 2.2 .+-. 0.2 1.9 .+-. 0.1 13.14 .+-.
12.15 0.23 .+-. 0.17 Values are means .+-. SD (n = 3 for each
value). MMAD, mass median aerodynamic diameter; GSD, geometric
standard deviation
EXAMPLE 9
Tissue Distribution and Pharmacokinetics of CPT-DLPC After Delivery
by Aerosol Generated With Normal or 5% CO2-Enriched Air
ICR mice are divided into two groups: the first group (n=4)
received CPT-DLPC formulation via aerosol generated with normal air
for 30 min, so their breathing parameters are not changed during
treatment; the second group (n=6) inhaled the same formulation but
in the atmosphere of 5% CO.sub.2-enriched air.
Inhalation of aerosols generated with 5% CO.sub.2-air caused a
significant increase in deposition of camptothecin into the lungs
(2.1-3.5-fold) (FIG. 1). CPT is detected at 134.+-.123 and
476.+-.216 ng/g of lung tissue of mice from the first and second
groups, respectively. The use of 5% CO.sub.2-in-air did not change
tissue distribution patterns. The concentrations of drug in the
liver, spleen, kidney, blood and brain after inhalation of CPT-DLPC
aerosol generated with 5% CO.sub.2-air are also increased.
The pharmacokinetic deposition of camptothecin in lungs during and
after 30 mins exposure to aerosols of CPT-DLPC using normal or 5%
CO.sub.2-air is determined (FIG. 2). The pulmonary concentrations
of camptothecin increased during the treatment with the maximum
concentration (Cmax) at the end of aerosol treatment (30 min.) and
subsequently lung concentrations started to decline. The peak
respiratory levels are 232.+-.158 and 486.+-.78 ng/g of the tissue
for normal and 5% CO.sub.2-air, respectively. During the 15 min
after the aerosol has been stopped, the concentrations of the drug
decrease exponentially. Clearing half-lives (T1/2) for both
treatments are 12-15 min. The profiles of the pharmacokinetic
curves are very similar for both types of treatment. Only trace
amounts of drug are detected in the lungs 90 min. after the end of
aerosolization (120 min. time point) with either air source.
EXAMPLE 10
Tissue Distribution and Pharmacokinetics of PTX Drug After
Treatment With Aerosol PTX-DLPC Generated by Normal or 5%
CO.sub.2-Enriched Air
Due to the limitations of the detection method, a liposomal
formulation of paclitaxel at 10 mg of PTX/ml suspension is used.
Mice are sacrificed halfway through exposure (15 min), at the end
of treatment (30 min), and at several time points following the end
of treatment. Mice are exposed to PTX-DLPC aerosol generated with
either normal air or air containing 5% CO.sub.2.
Pulmonary paclitaxel Cmax values are achieved at the end of
treatment (30 min) with either air source (FIG. 3). In the 5%
CO.sub.2-enriched air group Cmax is 4.2-fold higher than in the
ambient air group (23.1.+-.4.3 and 5.5.+-.0.2 .mu.g/g,
respectively). This carbon dioxide induced enhancement is unrelated
to the liposomal formulation (FIG. 4). Sterically stabilized
paclitaxel liposomes prepared using dismyristylphosphoethanolamine
poly (ethylene glycol) 2000 and dilauroylphosphatidylcholine are
deposited in the lung at equivalent levels when 5% CO2-in-air is
utilized.
Treatment with 5% CO2 produced 5.7-fold higher area under the
lung-concentration-time curve compared to normal air (33.7 and 5.9
.mu.g-hr/g, respectively). In both cases PTX concentrations started
to decrease from the pulmonary tissue after the treatment ended.
T1/2.alpha. and T1/2.beta. values for paclitaxel in the lungs are
0.3 and 1.6 hr, respectively, when normal air is used for aerosol
generation. T1/2.alpha. is 0.7 hr and T1/2.beta. is 5.1 hr for
paclitaxel administered by liposome aerosol produced with 5%
CO.sub.2-air. Comparative analysis for the other organs, such as
liver, spleen, kidney and blood was performed; however, the levels
of paclitaxel in these tissues using normal air for aerosolization
are below detectable levels.
The tissue distribution of paclitaxel after liposome aerosol
delivery using 5% CO.sub.2-air is presented in Table 2. The highest
concentration of the drug are detected in the lungs. Lower
concentrations are found in the other organs. Analysis of the area
under the concentration-time curve (AUC) over a 3 hr. period for
different organisms using the trapezoidal rule shoes the following
AUC values for lungs, liver, kidney, blood and brain: 34.+-.2,
9.8.+-.1.9, 2.4.+-.1.4, 2.8.+-.1.5, 0.13.+-.0.10, 0.23.+-.0.2 .mu.g
PTS-hr/g of tissue, respectively.
TABLE-US-00002 TABLE 2 PTX deposition in tissues during and after
30 min exposure to aerosol PTX-DLPC* generated with 5% CO2-air PTX
concentration (.mu.g/g of tissue) Time (hr) Lungs Liver Spleen
Kidney Blood Brain 0.25 20.3 .+-. 7.8 1.5 .+-. 0.8 0.6 .+-. 0.3 1.4
.+-. 0.0 0.25 .+-. 0.03 0.14 .+-. 0.16 0.5 23.1 .+-. 4.3 5.7 .+-.
3.0 1.4 .+-. 0.9 1.6 .+-. 0.1 0.18 .+-. 0.08 0.16 .+-. 0.02 0.75
18.0 .+-. 3.6 5.5 .+-. 1.8 0.5 .+-. 0.4 1.4 .+-. 0.1 0.08 .+-. 0.09
0.11 .+-. 0.03 1.0 14.8 .+-. 9.5 4.8 .+-. 3.9 2.6 .+-. 2.7 1.2 .+-.
0.7 0.07 .+-. 0.07 0.11 .+-. 0.03 1.5 8.7 .+-. 2.8 2.8 .+-. 0.8 1.0
.+-. 1.6 0.7 .+-. 0.3 0.03 .+-. 0.06 0.09 .+-. 0.08 2.0 6.5 .+-.
2.9 3.1 .+-. 0.7 0.6 .+-. 0.4 0.4 .+-. 0.3 0.01 .+-. 0.02 0.04 .+-.
0.04 3.0 7.1 .+-. 2.8 9.3 .+-. 0.6 0.5 .+-. 0.2 0.4 .+-. 0.1 0.01
.+-. 0.02 0.05 .+-. 0.05 Values are means .+-. SD of three
experiments (organs from 3 mice were combined and processed in each
experiment
EXAMPLE 11
Effect of Carbon Dioxide Induced Respiratory Patterns on Drug
Deposition
The increased pulmonary drug concentrations found in the lungs
after inhalation of 5% CO.sub.2-in-air could be explained by
changed respiratory patterns. Breathing patterns of mice in the
atmosphere of 5% CO.sub.2-enriched air are visually observed to
become deeper and slower and to return to normal almost immediately
after the end of treatment. Histological analysis did not reveal
any changes in pulmonary tissue. Plethysmograph studies that have
been performed by other researchers have demonstrated that
inhalation of 5% CO.sub.2-enriched air increased ventilation in
mammalians primarily because of the increase in tidal volume
(approximately 170-180%) (18,19). The average pulmonary deposition
of camptothecin and paclitaxel increased approximately 2-4-fold.
This disproportion with the increased of tidal volume may be due to
some other physiological changes in breathing parameters, e.g.,
breathing frequency, respiratory duration of inspiratory and
expiratory cycles, and minute ventilation (13). By deep and
complete expiration with breath holding the retention of the
aerosol increased almost twice in comparison with normal breathing
(15).
EXAMPLE 12
Preparation of PEI-DNA Complexes
PEI (25 kDa, branched) was purchased from Aldrich Chemical
(Milwaukee, Wis.). A PEI stock solution was prepared at a
concentration of 4.3 mg/ml (0.1 M in nitrogen) in PBS, pH 7-7.5.
PEI and DNA are mixed separately in 5 ml water at the required
concentrations. The PEI solution is slowly vortexed and the DNA
solution is added to it to make a final volume of 10 ml. The
mixture is alloed to stand at room temperature for about 15-20 min.
before nebulization. The resulting charge ratio is expressed as PEI
nitrogen:DNA phosphate (N:P), which can be calculated by taking
into account that DNA has 3 nmol of phosphate per microgram and 1
.mu.l of 0.1 M PEI solution has 100 nmol of amine nitrogen. A 10:1
N:P ratio corresponds to a 1:29:1 PEI:DNA weight ratio.
EXAMPLE 13
Aerosol Delivery of PEI:DNA Complexes
Mice are placed in plastic cages that are sealed with tape before
aerosol delivery (48). This is an unrestrained, wholebody aerosol
exposure system. PEI-DNA complexes are aerosolized using an
Aero-Mist nebulizer (CIS-US, Inc., Bedford, Mass.) at 10 liters/min
flow rate using air or air containing 5% CO2. Aero-Mist is a
high-output, efficient nebulizer demonstrated to produce aerosols
in the optimal range of 1-2 .mu.m MMAD with a geometric standard
deviation (GSD) of 2.9 using an Andersen cascade impactor (Andersen
Instruments, Atlanta, Ga.) by a method previously described (50). A
source of dry air (Aridyne 3500, Timeter, Lancaster, Pa.) is
delivered to a Brid 3M gas blender (Palm Springs, Calif.) attached
to an air compressor and a CO.sub.2 tank. The resulting mixture of
air and CO.sub.2 is delivered to the nebulizer. The final
concentration of 5% CO.sub.2 in air is determined using a Fyrite
solution (Bacharach, Pittsburgh, Pa.). Nebulization of 10 ml
solution took approximately 30 min.
EXAMPLE 14
CAT Assay
Mice are anesthetized and sacrificed after each time point and the
lungs and other tissues are harvested, weighted, and immediately
frozen. A CAT ELISA kit (Boehringer Manheim GmbH, Mannheim,
Germany) is used for measuring in vivo expression. The tissues are
homogenized in 700 .mu.l CAT assay lysis buffer using a Wig-L-Bug
bead homogenizer (Crescent Dental Mfg., Lyons, II). After
centrifuging the homogenates, 200 .mu.l of the extract is used for
the CAT ELISA performed in a 96-well plate format. The absorbance
is read using a microtiter plate reader (Molecular Devices,
Sunnyvale, Calif.). Naive mice are used as controls. The CAT
activity is expressed as ng of CAT/g of tissue using a standard
curve prepared with purified CAT enzyme. The sensitivity of the
assay is further enhanced according to suggestions from the
manufacturer so that it can detect levels of CAT protein as low as
0.1-0.3 pg/well.
EXAMPLE 15
Luciferase Assay
Mice are anesthetized and sacrificed and the lungs are harvested. A
luciferase assay kit (Promega) is used to measure luciferase
expression. The lungs are homogenized in 1 ml of luciferase assay
lysis buffer using a Wig-L-Bug bead homogenizer. After centrifuging
the homogenates, 10 .mu.l of the extract is added to 50 .mu.l of
luciferase substrates and the luminescence read for 10 s in a
96-well plate on a luminometer (Microlumat LB 96 P, EG & G
Berthold, Germany). Naive mice are used as controls. The luciferase
activity is expressed as RLU/10s/g of tissue. In this system,
10.sup.7 RLU corresponds to 1 ng of luciferase using purified
luciferase from Promega.
EXAMPLE 16
Histological Analysis of Tissue Sections
Mice are anesthetized with isoflurane and sacrificed by
exsanguination via the abdominal aorta. Lungs are isolated,
cannulated, and fixed by inflation with 10% neutral buffered
formalin, embedded in paraffin, and processed for histolgical
analysis. Thin sections are cut at 4 .mu.m and observed under the
microscope for any sings of inflammation or toxicity using the
hematoxylin and eosin stain.
EXAMPLE 17
Myeloperoxidase (MPO) Assay
Twenty-four hours after aerosol exposure, mice are anesthetized
with isoflurane and sacrificed by exsanguination via the abdominal
aorta. The lungs are harvested after perfusion through the heat
with saline. The tissue is homogenized in
hexadecyltrimethylammonium bromide (0.5% HTAB in 50 mM phosphate
buffer, pH 6.0; 5 ml HTAB/g of tissue) as previously described
(51). After centrifugation, the MPO activity in t h e supernatant
is determined using o-diasinidine dihydrochloride (0.167 mg/ml)
plus 0.0005% hydrogen peroxide. The absorbance is measured at 460
nm using a microtiter plate reader (Molecular Devices). The
absolute values after 15 min are recorded. Naive mice are used as
controls.
EXAMPLE 18
Nebulization of PEI-DNA Complexes With 5% CO.sub.2 Enhances the
Transgene Expression in Lung Compared to Normal Air
Breathing 5% CO.sub.2 in air has been associated with as increase
in the tidal volume and breathing frequency in mice and humans
(52-54). When 5% CO.sub.2-in-air is utilized to deliver the PEI-DNA
aerosol, the mice can be visually observed to be breathing deeper
and more rapidly. Inhalation of aerosols containing 5% Co.sub.2
could lead to greater inhalation of aerosol particles and
correspondingly higher transgene expression compared to that
achieved with aerosol delivered by air due to increased tidal
volume and breathing frequency.
PEI-DNA complexes are delivered to Balb/C mice by aerosol using
either normal air or air containing 5% CO.sub.2. A fixed amount of
CAT plasmid (1 mg/10 ml of solution), at a N:P ratio of 10:1, is
aerosolized for 30 min as indicated above. The lungs are harvested
after 24 h and CAT assay is performed to determine the degree of
transfection. Five percent CO.sub.2-in-air lead to a three-fold
increase (P=0.001) in the levels of CAT detected compared to
aerosol nebulized with air alone (FIG. 5). Also, 5% CO.sub.2 does
not change the particle size of the resulting drug-liposome aerosol
particles.
Enhancement of PEI-DNA transfer to the lung b y aerosol using
different percentages of CO.sub.2-in-air with a fixed amount of CAT
plasmid is also examined. The complexes are aerosolized using 0%,
2.5%, 5%, 10% and control amounts of carbon dioxide in air. The CAT
activity assayed indicates using either 2.5% or 10% provides as
good a level of transfection as using 5% CO.sub.2-in air (FIG.
6).
It is possible that enhanced CO.sub.2 has an effect on the
transfection efficiency of PEI-DNA complexes by changing some other
physiological parameters. However, CO.sub.2 does not significantly
alter the pH of the PEI-DNA solution nor does the particle size of
the resulting aerosol droplets, as compared to those of air,
significantly change. The increase in transgene expression in the
lungs is most likely due to increased deposition of aerosol
particles. Five percent CO.sub.2-in-air also could help to optimize
the aerosol delivery of other polymer-DNA or cationic lipid-DNA
complexes (45). This percentage of CO.sub.2 has been well tolerated
by humans and has been shown to increase the minute volume (54,55),
so this strategy could be efficacious against pulmonary diseases in
humans provided that the size, geometry and physiology of the human
pulmonary system is taken into consideration.
EXAMPLE 19
DNA Transfer by PET is Dose Dependent
To further optimize the transgene expression, the N:P ratio is kept
constant at 10:1 and the amount of DNA is varied from 250 .mu.g to
4 mg per 10 ml of the aerosolized solution. This leads to an
increase in the reservoir concentration as well as the amount of
total DNA nebulized in the aerosol output.
The nebulized output from the Aerotech II nebulizer was calculated
to be approximately 80%. About 72% of the reservoir DNA was
delivered to the inhalation chamber as estimated using an all-glass
impinger (AGI) (50). The remainder was trapped in the T-connector
and tubing. Based on murine obligate nasal breathing, pulmonary
physiology (minute volume and deposition fraction) (50), and the
output concentration of aerosol (4.8 ug/liter), the amount of DNA
deposited in the lungs of a mouse is estimated to be approximately
4-5 .mu.g during 30 min of aerosol exposure (for a starting
reservoir concentration of 2 mg DNA/10 ml solution). These
calculations are based on normal air breathing; the deposition
could be higher in the presence of 5% CO.sub.2 due to the increased
tidal volume and breathing frequency (53).
The complexes are aerosolized using 5% CO.sub.2-in-air with 2 mg
DNA giving the highest level of CAT expression in the lung (FIG.
7). The levels of CAT measured with 250 .mu.g DNA are not
statistically different from control lungs (P=0.34). Also, when 4
mg of DNA is dissolved in 10 ml at a N:P ratio of 10:1, it leads to
some visual precipitation of the DNA, whcih may account for no
further increase in the level of CAT detected in the lungs compared
to 2 mg (P=0.51).
It should be noted that there is an increase in both the
concentration and the amount of DNA delivered. However, it may be
possible to further increase the expression in the lung b y
increasing the exposure time of aerosol at the optimal
concentrations. These expression levels in the lung are comparable
to those using other delivery systems (34).
EXAMPLE 20
Optimization of PEI-DNA Ratios
Although PEI can protect the DNA during nebulization and also
result in higher transgene expression in the lungs after aerosol
delivery when compared to most other cationic lipids, determination
of optimal parameters for gene delivery is beneficial. The charge
interaction between any cationic vehicle and the negatively charged
DNA is an important factor determining the efficiency of the
transfection of the complex. Previous studies have examined the
optimum PEI-DNA (N:P) ratio for transfection in the lung (38, 56).
However, these studies involved an intravenous mode of PEI-DNA
delivery. Gene delivery by aerosol could require different
conditions.
To determine the charge ratio that would be ideal for in vivo
aerosol delivery, different PEI-DNA (N:P) ratios for their ability
to transfect the lung are evaluated. The amount of DNA is kept
constant at 2 mg and the PEI concentration is varied to obtain
ratios of 5:1, 10:1, 12.5:1, 15:1, 17.5:1, and 20:1. These ratios
are chosen based on previous in vitro and in vivo (by installation)
studies (43). The complexes are aerosolized using 5%
CO.sub.2-in-air. A N:P ratio of 15:1 gave the highest level of CAT
expression in lung, whereas 5:1 resulted in a very low level of CAT
expression (FIG. 8). There is statistically no difference between
10:1, 12.5:1, 15:1, 17.5:1, and 20:1 ratios (P>0.1), but a
significant difference between 15:1 and 20:1 (P=0.05) and between
10:1 and 15:1 (P=0.014).
To determine the optimal ratio for a plasmid other than CAT,
different N:P ratios for the expression of the luciferase gene in
the lung are tested. The ratios evaluated are 5:1, 10:1, 15:1,
20:1, 30:1, and 40:1. The optimum curve for luciferase shifted to
the right compared to CAT, with the highest expression at 20:1
(P<0.05 compared to other ratios) (FIG. 8). This suggests that
different plasmids might require different N:P ratios; the
different size of luciferase plasmid leads to a structurally
different complex with FE compared to that of the CAT plasmid. It
could also be due to a difference in plasmid purity and the
proportion of supercoiled structure. Still there is a considerable
overlap in the optimum N:P ratios of these two plasmids. The
optimum ratios for different plasmids may be different. Considering
experimental variability, a ratio between 10:1 and 20:1 should work
suitably. A ratio lower than 10:1 did not give very high
transfection in the lung. These results are in agreement with those
obtained using branched 25K PEI although the mode of delivery was
intravenous (56).
EXAMPLE 21
Time Course of CAT Expression in Lung Following Single Aerosol
Delivery
CAT expression was also used to monitor the time course of gene
expression. The analysis of the persistence of CAT expression
following a single aerosol delivery provides important information
for planning a treatment regime for therapeutic studies. Two
milligrams of CAT plasmid is aerosolized, using 5% CO.sub.2-in-air,
to the mice at two different N:P ratios, 15:1 and 10:1. Different
time points examined for the 10:1 group are 1, 2, 3, and 6 days
post aerosol exposure. Lungs and other tissues are harvested at
different time points and frozen immediately. All tissues are
assayed simultaneously after the last time point (day 6). For the
15:1 group the mice are sacrificed 1, 3, 7, and 10 days after
aerosol treatments. The lungs are harvested, weighed, and frozen
after each time point and the CAT protein is assayed after the last
time point (day 10).
For both N:P ratios examined, the CAT expression is highest at 24 h
and remains constant (statistically no difference between day 1 and
day 3, P=0.4 for the 15:1 ratio and P=0.12 for the 10:1 ratio) for
over three days (FIGS. 10A and 10B). The CAT level falls to about
50% of peak levels after a week and significant levels are detected
even after 10 days (P=0.001 compared to control). This suggests
that the delivery may be more than adequate for a variety of
clinical applications. The persistence of gene expression up to day
10 is similar to or greater than that of other cationic lipids used
for installation or aerosol delivery of genes (34,58).
EXAMPLE 22
Tissue distribution of Transgene
Intravenous or intraperitoneal delivery of DNA vectors generally
results in expression in a variety of tissues. In order to
determine if aerosol delivery of PEI-DNA results in systemic gene
delivery, different tissues are harvested from the same group of
mice as the above experiment (from the 10:1) group) and the CAT
assay is performed after the last time point. The tissues examined
are lung, liver, spleen, kidney, thymus, brain, and blood. The
level of CAT detected in non-lung tissues was very low and not
significantly different (P>0.1 for all the tissues) from the
control tissues (FIG. 11).
The tissue distribution data show that gene expression following
aerosol delivery in this system is confined to the lung, indicating
minimal systemic delivery. In contrast to the lung, tissues such as
liver, spleen, and kidney, which normally exhibit detectable levels
of expression when genes are delivered via intravenous or
intrapertioneal administration, exhibited insignificant or no
detectable CAT expression when delivered by PEI-DNA aerosol. This
is important if the expression of the gene of interest is to be
restricted to the lungs. In other studies, the intratracheal mode
of gene delivery has been used to localize the gene to the lungs
(58). However, this is a rather invasive technique compared to
aerosol and generally results in less uniform deposition to the
peripheral regions of the lung. Aerosol delivery helps to
distribute the particles noninvasively and uniformly through out
the lungs (49).
EXAMPLE 23
Histological Analysis Shows No Signs of Inflammation
In order to determine if aerosol delivery of PEI-DNA complexes
leads to any kind of toxicity or acute inflammation in this system,
two milligrams of CAT plasmid is complexed with PEI at a N:P ratio
of 15:1 and the mice are exposed to aerosol for 30 min using 5%
CO.sub.2-in-air. The mice are sacrificed after 24 h and the lungs
are fixed in formalin and stained with hematoxylin and eosin. The
lungs did not show any evidence of histological abnormality, e.g.,
inflammatory cell infiltration or damage to the lungs when thin
sections are examined (FIG. 12). Use of 5% CO.sub.2-in-air to
optimize pulmonary gene delivery of PEI-DNA aerosol seems to be
safe and highly specific for the lung.
Although high levels of expression are detected in this system even
a week after single aerosol exposure, some therapies may require
repeated and frequency delivery of genes. The effects of prolonged
PEI-DNA aerosol exposure on lungs and other tissues needs to be
determined.
EXAMPLE 24
Myeloperoxidase Assay Does Not Reveal Any Inflammation
Acute pulmonary inflammation is mediated in part by
polymorphonuclear leukocyte (PMN) sequestration to the peripheral
tissues. A biochemicl marker for polymorphonuclear leukocyte is
myeloperoxidase (MPO), which is a heme-containing enzyme found in
the azurophilic granules and its often utilized as an inflammation
marker in the lungs (18). To assess neutrophil infiltration into
the lungs, 2 mg of CAT plasmid is complexed with PEI at a N:P ratio
of 15:1 and the mice are exposed to aerosol for 30 min using 5%
CO.sub.2-in-air. The mice are sacrificed after 24 h, the lungs were
harvested, and the myeloperoxidase assay is performed (Table
3).
The myeloperoxidase contents in the control and aerosol-exposed
lungs were not significantly different (P=0.92). The
myeloperoxidase assay did not reveal any difference between the
control and aerosol-exposed lungs, i.e., there is no difference in
the absolute absorbance values (OD) between control and
aerosol-exposed lungs, even 15 min after incubation of the reaction
(OD of 0.078.+-.0.009 for control and 0.084.+-.0.004 for
aerosol-exposed lungs, P>0.5).
TABLE-US-00003 TABLE 3 Myeloperoxidase (MPO) Assay for Evaluation
of Neutrophil Infiltration into the Lungs Group Control Aerosol
Lung MPO activity 0.0398 .+-. 0.01 0.0404 .+-. 0.008
(.delta.A/min/g tissue) Note. Two milligrams of CAT plasmid was
complexed with PEI at a N:P ratio of 15:1 and the complex was
aerosolized to five mice for 30 min using 5% CO2-in-air. Mice were
sacrificed 24 h later, lungs were harvested, and the MPO assay was
performed. Values are means .+-. SD (n = 5 mice per group).
EXAMPLE 25
P53 Assay
P53 expression was examined using an ELISA kit (Roche Diagnostics,
Indianapolis, Ind.). For in vitro expression, B16-F10 cells grown
in tissue culture plates (20,000 cells/well in a 48-well plate)
were transfected with PEI:DNA complexes for 24 h. The cultures were
then washed and cells lysed using cell lysis buffer. After
centrifugation, 100 .mu.l of the lysate was used for p53 ELISA. The
p53 levels were normalized to the total protein content measured by
the BCA protein assay (Pierce, Rockford, Ill.). For in vivo
expression, mice were exposed to PEI:p53 aerosol, sacrificed 24 h
later and the lungs harvested and weighed. The lungs were
homogenized in 1 ml of ice cold cell lysis buffer (20 mM Tris, 0.5
mM EDTA, 1% Nonidet P40, 0.05% SDS, 1 mM PMSE, 1 .mu.g/ml
pepstatin, 2 .mu.g/ml leupeptin) using a Wig-L-Bug bead homogenizer
(Crescent, Lyons, Ill.). After centrifugation at 4.degree. C., 100
.mu.l of the supernatant was used for p53 ELISA performed in a
96-well plate. The absorbance (450 nm) was read in triplicate using
a Molecular Devices (Sunnyvale, Calif.) microtiter plate reader.
The amount of p53 was determined using a standard curve prepared
with purified 053. The assay can detect p53 levels as low as 10
pg/ml and the linear measuring range of the assay is 50-1000 pg/ml.
The total protein content in the lungs was determined using the BCA
protein assay.
EXAMPLE 26
P53 Expression in Mouse Lung Following Aerosol Delivery of PEI-p53
Complexes
PEI-p53 complexes are prepared as done for PEI:DNA complexes
described above. Two milligrams of p53 plasmid is complexed with
polyethylenimine at a PEI:DNA (N:P) ratio of 10:1 and aerosolized
to the C57BL/6 mice using 5% CO.sub.2-in-air. Mice were placed in
plastic cages that were sealed with tape before aerosol delivery.
This is an unrestrained, whole body aerosol exposure system.
PEI-p53 complexes were aerosolized using an Aero-Mist nebulizer in
the presence of 5% CO.sub.2 as described for aerosolization of
polyethyleneimine:CAT complexes previously herein.
P53 expression in lung was analyzed by ELISA 24 h after aerosol
delivery of the PEI-p53 complexes to the mice. Aerosol delivery of
complexes lead to about a four fold increase in the levels of p53
detected in the lung tissue compared to that detected in the lings
of naive mice. The level of p53 in the control mice is
0.0398.+-.0.01 pg/mg protein and the level in the aerosolized mice
is 0.0404.+-.0.008 pg/mg protein (values are means.+-.SD) (59).
Exposure to PEI-Luc did not result in any increase in the p53
levels (data not shown).
EXAMPLE 27
Inhibition of B16-F10 Lung Metastasis by Aerosol Delivery of
PET-p53
C57BL/6 mice were injected intravenously with 25,000 B16-F10 cells
on day 0. The mice were treated with polyethylenimine-p53 aerosol
complexes generated using 5% CO.sub.2 twice a week starting the day
after inoculation of the cancer cells into the mice (on days 1, 4,
8, 11, 15, 18, and 22) with the last treatment on day 22
postinjection (a total of seven aerosol exposures). Control groups
included untreated mice, mice treated with polyethyleneimine or
with polyethylenimine-Luc aerosol complexes. The control animals
start dying around day 24 post tumor cell inoculation, which is
when the therapy was stopped and the experiment terminated. The
dosage of treatment was 2 mg plasmid/10 ml of aerosolized solution
at a polyethyleneimine:DNA (N:P) ratio of 10:1. This is the total
amount of DNA aerosolized to the mice. The mount of DNA delivered
per mouse is estimated to be about 4-5 .mu.g in the presence of
normal air and is increased in the presence of 5% CO.sub.2 due to
the increase in tidal and minute volumes.
On day 24 post tumor inoculation, the mice were sacrificed and the
lungs fixed and tumor index was calculated. The mice treated with
PEI-p53 has a very low tumor index (P<0.001 compared to all
other groups) whereas all the control groups had large number of
tumor nodules (FIGS. 13A, 13B). A majority of untreated mice and
mice treated with either polyethylenimine alone or with
polyethyleneimine-Luc had numerous uncountable tumor nodules with
concomitant invasion into the chest wall and had metastases in
extrapulmonary tissue such as the neck and abdominal lymph nodes.
However, all of the mice treated with polyethyleneimine-p53
complexes had very small and distinct tumor foci with no invasion
into the chest wall and no extrapulmonary metastatic tumors. There
was no effect of 5% CO.sub.2 alone on the growth of tumors compared
to untreated mice (data not shown). The lung weights also showed a
significant difference (P<0.0 1) between PEI-p53 treated group
and all the control groups (FIG. 13C).
The following references are cited herein. 1. Persons et al.,
Airway deposition of hygroscopic heterodispersed aerosols: results
of a computer model. J. Appl. Physiol. 63:1195-1204 (1987). 2.
Persons et al., Maximization of pulmonary hygroscopic aerosol
deposition. J. Appl. Physiol. 63: 1205-1209 (1987). 3. Schlenker,
E. H. Ventilation and metabolism of the djungarian hamster
(Phodopus sungorus) and the albino mouse. Comp. Biochem. Physiol.
82A:293-295 (1985). 4. Nielsen, et al., Ventilation, CO2
Production, and CO2 exposure effects in conscious, restrained CF-1
mice. Pharmacol. Toxicol. 72: 163-168 (1993). 5. Goldring, et al.,
Respiratory adjustment to chronic alkalosis in man. J. Clin. Inv.
47: 188-202. 6. Stegen, et al., Biological Psychology 49:109-122
(1998). 7. Hallman, M., et al., Inositol Supplementation in
Premature Infants with Respiratory Distress Syndrome, N. Eng. J.
Med. 326:1233-1239 (1992). 8. Knight, V., Viral and Mycoplasmal
Infections of the Respiratory Tract. 1973, Lea and Febiger, Phila.
Pa., pp. 2. 9. Kay, B., Allergy and Allergic Diseases, Blackwell
Publications, Oxford, England, Vol. I pp. 730-741 (1997). 10.
Burke, et al., Liposomal stabilization of camptothecin's lactone
ring. J. Am. Chem. Soc. 114:8318 (1992). 11. Cabanes et al.,
Comparative in vivo studies with paclitaxel and
liposome-encapsulated paclitaxel. Int. J. Oncol. 12: 1035 (1998).
12. Daoud, et al., Antitumor effect of liposome-incorporated
camptothecin in human malignant xenografts. Anticancer Drugs 6: 83
(1995). 13. Davis, J. N. and Staag, D. Interrelationships of the
volume and time components of individual breaths in resting man. J.
Physiol. 245: 481 (1975). 14. Gottschalk, et al., Fundamental
investigations for the deposition of aerosols from radioactive
solutions in the upper and lower airways. Z. Erkr Atmungsorgane
153: 355 (1979). 15. Hershey, et al., Inhalation chemotherapy for
macroscopic primary or metastatic lung tumors: proof of principle
using dogs with spontaneously occurring tumors as a model. Clin.
Cancer Res. 5: 2653 (1999). 16. Knight et al., Anticancer effect of
9-nitrocamptothecin liposome aerosol on human cancer xenografts in
nude mice. Cancer Chemother. Pharmacol. 44: 177 (1999). 17.
Koshkina, et al., Distribution of camptothecin after delivery as a
liposome aerosol or following intramuscular injection in mice.
Cancer Chemother. Pharmacol. 44: 187 (1999). 18. Koshkina, et al.,
9-Nitrocamptothecin liposome aerosol treatment of melanoma and
osteosarcoma lung metastases in mice. Clin. Cancer Res. (in press).
19. Mortola, J.P. and Lanthier, C. Theventilatory and metabolic
response to hyprcapnia in newborn mammalian species. Respiration
Physiol. 103:263. 20. Nielsen, et al., Ventilation, CO2 production,
and CO2 exposure effects in conscious, restrained CF-1 mice.
Phrmcol Toxicol. 72:163 (1993). 21. Rajkumar, S. V. and Adjei, A.
A. A review of the pharmacology and clinical activity of new
chemotherapeutic agents in lung cancer. Cancer Treat Rev. 24: 35-3
(1998). 22. Rowinsky, E. K. and donehower, R. C. Drug therapy:
paclitaxel (Taxol). N. Engl. J. Med. 332: 1004 (1995). 23. Sharma,
et al., Activity of paclitaxel liposome formulations against human
ovarian tumor xenografts. Int. J. Cancer 71: 103 (1997). 24.
Socinski, M. A. Single-agent paclitaxel in treatment of advanced
non-small lung cancer. Oncologist 4: 408 (1999). 25. Stehlin, et
al., Phase I clinical trail and pharmacokinetics results with oral
administration of 20-(S)-camptothecin. In: Potmesil M., Pinedo, H.,
eds. Camptothecins, new anticancer agents. CRC Press. Boca Raton,
Fla.: 59 (1995). 26. Steward, W. P. and Dunlop, D. J. New drugs in
the treatment of non-small cell cancer. Ann. Oncol. 6: S49 (1995).
27. Sugarman, et al., Lipid-complexed camptothecin: formulation
andinitial biodistribution and antitumor activity studies. Cancer
Chemother. Parmacol. 37: 531 (1996). 28. Verschraegen, et al., A
phase I clinical and pharmacological study of oral
9-nitrocamptothecin, a novel water-insoluble topoisomerase I
inhibitor. Anti-Cancer Drugs 9: 36 (1998). 29. Vidgren, et al., A
study of .sup.99mtechnetium-labelled beclomethasone dipropionate
dilauroylphosphatidylcholine liposome aerosol in normal volunteers.
Int. J. Pharm. 115: 209 (1999). 30. Waldrep, et al., Operating
characteristics of 18 different continuous-flow jet nebulizers with
beclomethasone dipropionate liposome aerosol. Chest 105: 106
(1994). 31. Waldrep, et al., High does cyclosporin A and
budesonide-liposome aerosols. Int. J. Pharm. 12: 27 (1997). 32.
Yamashiro, et al., Total work rate of breathing optimization in
CO2-inhalation and exercise. J. Appl. Physiol. 38: 702 (1975). 33.
Templeton et al., Improved DNA:lipsomoe complexes for increased
systemic delivery and gene expression. Nat. Biotechnol. 15: 647-652
(1997). 34. Eastman, S. J., et al. A concentrated and stable
aerosol formulation of cationic lipid:DNA complexes giving high
level gene expression in mouse lung. Hum. Gene Ther. 8: 165-773
(1997). 35. Li, S., and Huang, L. In vivo gene transfer via
intravenous administration of cationic lipid-orotamine-DNA (LPD)
complexes. Gen. Ther:. 4:891-900 (1997). 36. Boussif, O., et al. A
versatile vector for gene and oligonucleotide transfer into cells
in culture and in vivi: Polyethyleneimine. Proc. Natl. Acad. Sci,
USA 92:7297-7301 (1995). 37. Godbey, et al., Tracking the
intercellular path of poly (ethylenimine)/DNA complexes for gene
therapy. Proc. Natl. Acad. Sci. USA 90: 5177-5181 (1999). 38.
Ferrari, et al., Polyethylenimine shows properties of interest for
cystic fibrosis gene therapy. Biochim. Biophys. Acta 1447: 219-225
(1999). 39. Goula, et al., Polyethylenimine-based intravenous
delivery of transgenes to mouse lung. Gene Ther. 5: 1291-1295
(1998). 40. Abdallah, et al., A powerful nonviral vector for in
vivo gene transfer into the adult mammalian brain:
Polyethylenimine. Hum. Gene. Ther. 7: 1947-1954 (1996). 41. Boleta,
et al., Nonviral gene delivery to rat kidney with
polyethyleneimine. Hum. Gene. Ther. 8: 1243-1251 (1997). 42. Coll,
et al., In vivo delivery to tumors fDNA complexed with linear
polyethylenimine. Hum. Gene Ther. 10: 1659-1666 (1999). 43.
Schwartz, et al., Delivery of DNA-cationic liposome complexes by
small particle aerosol. Hum. Gene Ther. 7: 731-741 (1996). 44.
Densmore, C. L., et al. Aerosol delivery of robust
polyethyleneimine-DNA complexes for gene therapy and genetic
immunization. Mol. Ther. 1: 180-188 (2000). 45. Densmore, et al.,
Gene transfer by
guanidiumcholesterol:dioleoylphosphatidyl-ethanolamine liposome-DNA
complexes in aerosol. J. Gene Med. 1: 251-264 (1999). 46. Ernst,
N., et al. Interactions of liposomal and polycationic transfection
complexes with pulmonary surfactant. J. Gene Med. 1: 331-340
(1999). 47. Liu, et al., Cationic liposome-mediated intravenous
gene delivery. J. Biol. Chem. 270: 24864-24870 (1995). 48.
Koshkina, et al., Distribution of camptothecin after delivery as a
liposome aerosol or following intramuscular infection in mice.
Cancer Chemother. Pharmocol. 44: 187-192 (1999). 49. Vidgren, M. et
al. A study of 99mtchnetium-labeled beclomethasone dipropionate
dilauroylphosphatidylcholine liposome aerosol in normal volunteers.
Int. J. Pharm. 115: 209-216(1995). 50. Knight, et al., Anticancer
effect of 9-nitrocamptothecin liposome aerosol on human cancer
xenografts in nude mice. Cancer Chemother. Pharmacol. 44:177-186
(1999). 51. Goldblum, et al., Lung myeloperoxidase as a measure of
pulmonary leukostasis in rabbits. J. Appl/ Physiol. 59: 1978-1985
(1985). 52. Schlenker, E. H. Ventilation and metabolism of the
djungarian hamster (phodopus sungorus) and the albino mouse. Comp.
Biochem. Physiol 82A: 293-295 (1985). 53. Nielsen, et al.,
Ventilation, CO2 production and CO2 exposure effects in conscious,
restrained CF-1 mice. Pharmacol. Toxicol. 72: 163-168 (1993). 54.
Goldring, et al., Respiratory adjustment to chronic metabolic
alkalosis in man. J. Clin. Invest. 47: 188-202 (1968). 55.
Goldring, et al., Regulation of alveolar ventilation in respiratory
failure. Am. J. Med. Sci. 269: 160-170 (1975). 56. Bagonzi, A., et
al. Comparison between cationic polymers and lipids in mediating
systemic gene delivery to the lungs. Gene Ther. 6: 1995-2004
(1999). 57. Lee, E. R., et al. Detailed analysis of structure and
formulations of cationic lipids for efficient gene transfer to
lung. Hum. Gene ther. 7: 1701-1717 (1996). 58. Meyer, et al.,
Intratracheal gene delivery to mouse airway: Characterization of
plasmid DNA expression and pharmacokinetics. Gene Ther. 2: 450-460
(1995). 59. Fidler, I. J., and Nicolson, G. L. Tumor cell and host
properties affecting the implantation and survival of blood-borne
metastatic variants of B16 melanoma Isr. J. Med. Sci. 14:38-50
(1978).
Any patents or publications mentioned in this specification are
indicative of the levels of those skilled in the art to which the
invention pertains. These patents and publications are herein
incorporated by reference to the same extent as if each individual
publication was specifically and individually indicated to be
incorporated by reference.
One skilled in the art will readily appreciate that the present
invention is well adapted to carry out the objects and obtain the
ends and advantages mentioned, as well as those inherent therein.
The present examples along with the methods, procedures,
treatments, molecules, and specific compounds described herein are
presently representative of preferred embodiments, are exemplary,
and are not intended as limitations on the scope of the invention.
Changes therein and other uses will occur to those skilled in the
art which are encompassed within the spirit of the invention as
defined by the scope of the claims.
* * * * *